Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

chevron_leftPreviosly
Lice feel the itch over Hatchtech deal
01 November 2013

You may also like

04 September 2017

Citadel Group aquires OneVentures portfolio company Charm Health

06 October 2020

Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

16 May 2018

Biomedical Translation Fund invests in further development of total artificial heart device

16 September 2018

VC-backed women’s health company Madorra to begin clinical trials in Australia

03 September 2012

Hatchtech announce successful End-of-Phase 2 for head lice product DeOvo™

30 November 2020

OneVentures Growth (Equity) Fund V combines capital and executional support to tech companies

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor